The American healthcare system is one of the world’s largest markets, nearly 18% of the U.S. GDP is spent on healthcare compared with Australia’s 9.6%, however their average life expectancy is 78.8 years vs. 80.7 – 83.9 years for other OECD (organisation for economic cooperation and development) countries. This is largely due to the U.S. healthcare system being one of the least efficient systems in the world.
CVS Health is an American retail pharmacy and healthcare company which, due to recently acquiring Aetna, also provides health insurance. The company has over 9,800 retail locations throughout the U.S. and in a number of South American countries including Columbia and Brazil. The scale of its pharmacy network enables CVS to negotiate discounts on drug prices on behalf of their subscribers, a scheme known as Pharmacy Benefit Management. Their company structure makes them one of only a few businesses that are fully aligned in trying to reduce healthcare costs, in line with the wants of both patients and regulators.
We’re attracted to this stock for two main reasons, the first being its vested interest in containing and reducing the cost of healthcare in the U.S. Due to the company’s insurance branch they are incentivised to ensure their clients stay in good health. This in turn benefits their customers who, not only remain healthy but also receive the pharmaceutical price reductions that CVS is able to pass on. The second reason is their historically cheap valuation of 9x PE and 8x EV/Ebitda compared with their five year average of 15x and 9x.
They are not the only company operating with this structure, United Health does something quite similar. These are really the only two vertically integrated healthcare businesses that have the insights and business model that benefit from successful population health management, saving cost in the healthcare system by delivering better healthcare outcomes.
We are therefore invested in this company for the following main reasons:
- Demand – there is high demand for their services of delivering better health outcomes at lower costs.
- Business model – their vertically integrated business model creates value by delivering superior health outcomes at a lower cost.
- Management – they have a strong and experienced management team that understand the strategic change in the US market and that has the capability to leverage the company’s assets to deliver value through responsibly run operations.
- Valuation – In our view, they are extremely attractively valued for this market position and quality of business.
This stock is currently held by our WHEB Sustainable Impact Fund.
This report has been prepared by Pengana Investment Management Ltd (ABN 69 063 081 612), Australian Financial Services Licence No. 219462) (“Pengana”). This report does not contain any investment recommendation or investment advice and has been prepared without taking account of any person’s objectives, financial situation or needs. Therefore, before acting on the information in this report a person should consider the appropriateness of the information, having regard to their objectives, financial situation and needs.
Pengana is the issuer of units in the Pengana WHEB Sustainable Impact Fund (ARSN 121 915 526) (“the Fund”). A Product Disclosure Statement for the Fund (“PDS”) is available and can be obtained by contacting Pengana on (02) 8524 9900. A person who is considering investing in the Fund should obtain the relevant PDS and should consider the PDS carefully and consult with their financial adviser to determine whether the Fund is appropriate for them before deciding whether to invest in, or to continue to hold, units in the Fund.
The value of investments can go up and down. Past performance is not a reliable indicator of past performance.
While care has been taken in the preparation of this report, Pengana makes no representation or warranty as to the accuracy, currency or completeness of any statement, data or value. To the maximum extent permitted by law, Pengana expressly disclaims any liability which may arise out of the provision to, or use by, any person of this report.
Get monthly insights and market commentary direct to your inbox